{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:10:22Z","timestamp":1791515422882,"version":"4.3.4"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jsbmb.2013.12.011","type":"journal-article","created":{"date-parts":[[2013,12,25]],"date-time":"2013-12-25T06:45:37Z","timestamp":1387953937000},"page":"142-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"special_numbering":"C","title":["Use of SERMs for treatment in postmenopausal women"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-3405","authenticated-orcid":false,"given":"JoAnn V.","family":"Pinkerton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2393-4338","authenticated-orcid":false,"given":"Semara","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2013.12.011_bib0005","first-page":"659","article-title":"Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens","volume":"9","author":"McDonnell","year":"1995","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1210\/mend.11.6.0009","article-title":"Coactivator and corepressor regulation of the agonist\/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen","volume":"11","author":"Smith","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0025","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/BOR.0b013e32832ca447","article-title":"New selective estrogen and androgen receptor modulators","volume":"21","author":"Clarke","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0030","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/en.2009-0721","article-title":"Molecular mechanism of the inhibition of estradiol-induced endometrial epithelial cell proliferation by clomiphene citrate","volume":"151","author":"Amita","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cell.2006.04.021","article-title":"The expanding cosmos of nuclear receptor coactivators","volume":"125","author":"Lonard","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0022-3565(24)38923-2","article-title":"Molecular mechanisms of selective estrogen receptor modulator (SERM) action","volume":"295","author":"Dutertre","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/gme.0b013e3181906fa3","article-title":"Designing the ideal selective estrogen receptor modulator \u2013 an achievable goal?","volume":"16","author":"Taylor","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0050","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1091\/mbc.e03-06-0360","article-title":"Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta","volume":"15","author":"Tee","year":"2004","journal-title":"Mol. Biol. Cell"},{"issue":"Suppl. 1","key":"10.1016\/j.jsbmb.2013.12.011_bib0055","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.maturitas.2004.03.006","article-title":"The molecular determinants of estrogen receptor pharmacology","volume":"48","author":"McDonnell","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators \u2013 mechanisms of action and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/mi.5.6.7","article-title":"Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting","volume":"5","author":"Hall","year":"2005","journal-title":"Mol. Interv."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0070","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/me.2004-0486","article-title":"Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes","volume":"19","author":"Bjornstrom","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0075","article-title":"Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy","author":"Pinkerton","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/13697137.2012.696289","article-title":"Bazedoxifene\/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention","volume":"15","author":"Pinkerton","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0085","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/gme.0b013e3181c4f1d6","article-title":"Endometrial safety: a key hurdle for selective estrogen receptor modulators in development","volume":"17","author":"Pinkerton","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2012.11.011","article-title":"The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis","volume":"53","author":"Nelson","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0095","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0100","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists\u2019 Collaborative Group","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0105","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0110","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0115","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0120","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1471-2407-12-161","article-title":"A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study","volume":"12","author":"Gu","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer","volume":"77","author":"Taras","year":"2001","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/gme.0b013e318223e82a","article-title":"Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model","volume":"19","author":"Burich","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0140","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","article-title":"Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women","volume":"24","author":"Komi","year":"2006","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1759720X11422602","article-title":"Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis","volume":"4","author":"Komm","year":"2012","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.maturitas.2010.05.009","article-title":"SERMs: progress and future perspectives","volume":"67","author":"Pickar","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0160","doi-asserted-by":"crossref","first-page":"821","DOI":"10.4065\/75.8.821","article-title":"Prevention and treatment of osteoporosis in women with breast cancer","volume":"75","author":"Mincey","year":"2000","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.2002.17.1.11","article-title":"Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density","volume":"17","author":"Riggs","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0170","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","article-title":"Meta-analysis of vascular and neoplastic events associated with tamoxifen","volume":"18","author":"Braithwaite","year":"2003","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0175","first-page":"141","article-title":"Long-term cardiac and vascular disease outcomes following adjuvant tamoxifen therapy: current understanding of impact on physiology and overall survival","volume":"104","author":"Onitilo","year":"2013","journal-title":"Minerva Med."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0180","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1161\/01.CIR.0000041044.93571.CA","article-title":"Influence of tamoxifen on carotid intima-media thickness in postmenopausal women","volume":"106","author":"Simon","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0185","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1161\/CIRCULATIONAHA.108.817577","article-title":"Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors","volume":"119","author":"Collins","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0195","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/CIRCULATIONAHA.109.924571","article-title":"Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial","volume":"122","author":"Ensrud","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0200","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2012","journal-title":"Menopause"},{"issue":"Suppl. 1","key":"10.1016\/j.jsbmb.2013.12.011_bib0205","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/13697130903010953","article-title":"Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women","volume":"12","author":"De Villiers","year":"2009","journal-title":"Climacteric"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0210","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/01.CIR.0000154545.84124.AC","article-title":"Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial","volume":"111","author":"Decensi","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0215","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0220","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0225","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/17425255.2010.487483","article-title":"Pharmacologic evaluation of ospemifene","volume":"6","author":"McCall","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0230","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.brainresrev.2005.01.009","article-title":"Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs","volume":"49","author":"Zhao","year":"2005","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.jsbmb.2013.12.011_bib0235","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.psyneuen.2009.04.012","article-title":"Neuroprotective actions of selective estrogen receptor modulators","volume":"34","author":"DonCarlos","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0240","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1677\/JME-10-0122","article-title":"Selective estrogen receptor modulators as brain therapeutic agents","volume":"46","author":"Arevalo","year":"2011","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0245","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0250","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1517\/14656560903127241","article-title":"Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy","volume":"10","author":"Gennari","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0255","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5122(99)00090-0","article-title":"Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials","volume":"34","author":"Cohen","year":"2000","journal-title":"Maturitas"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0260","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/gme.0b013e3182176285","article-title":"Selective estrogen receptor modulators and their effects on hot flashes: a dilemma","volume":"18","author":"Bouchard","year":"2011","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0265","series-title":"Presented at the 89th Annual Meeting of the Endocrine Society, June 2\u20135","article-title":"RAD-1901, a novel SERM, has efficacy in an animal model of vasomotor symptoms","author":"Hattersley","year":"2007"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0270","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/GME.0b013e318031a83d","article-title":"The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety","volume":"14","author":"Stovall","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0275","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/13697130802657896","article-title":"Pharmacology and clinical applications of selective estrogen receptor modulators","volume":"12","author":"Nath","year":"2009","journal-title":"Climacteric"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0280","unstructured":"Nolvadex\u00ae (tamoxifen citrate) Prescribing Information. AstraZeneca."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0285","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0290","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Osborne","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0295","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0300","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0305","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0310","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0315","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0320","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0325","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"22","author":"Sverrisdottir","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0330","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0335","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/jnci\/djh007","article-title":"Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer","volume":"96","author":"Curtis","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cncr.22734","article-title":"Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen","volume":"110","author":"Saadat","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0345","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2008.08.035","article-title":"Relationship between tamoxifen use and high risk endometrial cancer histologic types","volume":"112","author":"Bland","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0350","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-007-9823-1","article-title":"Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer","volume":"112","author":"Hoogendoorn","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0355","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/jnci\/dji057","article-title":"Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case\u2013control study","volume":"97","author":"Swerdlow","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0360","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/cncr.20347","article-title":"The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review","volume":"101","author":"Deitcher","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0365","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2005.09.007","article-title":"Toremifene: an evaluation of its safety profile","volume":"15","author":"Harvey","year":"2006","journal-title":"Breast"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0370","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1005891506092","article-title":"A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group","volume":"45","author":"Gershanovich","year":"1997","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0375","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.1995.13.10.2556","article-title":"Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer","volume":"13","author":"Hayes","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0380","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1997.375","article-title":"Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the \u2018nordic\u2019 phase III study","volume":"76","author":"Pyrhonen","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0385","series-title":"Medications for Risk Reduction of Primary Breast Cancer in Women","year":"2013"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0390","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0395","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.162.10.1140","article-title":"Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis","volume":"162","author":"Maricic","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0400","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","article-title":"Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial","volume":"33","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0405","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","article-title":"Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial","volume":"33","author":"Delmas","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1472-6874-13-15","article-title":"Fractures in women treated with raloxifene or alendronate: a retrospective database analysis","volume":"13","author":"Foster","year":"2013","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0415","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2007.14.0921","article-title":"Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case\u2013control study","volume":"26","author":"DeMichele","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0420","first-page":"346","article-title":"Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy","volume":"101","author":"Parsons","year":"2003","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0425","first-page":"45","article-title":"Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women","volume":"10","author":"Pinkerton","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0430","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women","volume":"12","author":"Komi","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0435","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0440","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.287.7.847","article-title":"Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial","volume":"287","author":"Barrett-Connor","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0445","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1176\/appi.ajp.162.4.683","article-title":"Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial","volume":"162","author":"Yaffe","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0450","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/jwh.2009.1605","article-title":"Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition","volume":"19","author":"Espeland","year":"2010","journal-title":"J. Womens Health (Larchmt)"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0455","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0460","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/gme.0b013e3181b7c65f","article-title":"A randomized, placebo- and active-controlled trial of bazedoxifene\/conjugated estrogens (BZA\/CE) for treatment of moderate to severe vulvar\/vaginal atrophy in postmenopausal women","volume":"17","author":"Kagan","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0465","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.steroids.2013.09.003","article-title":"Tissue selectivity of ospemifene: pharmacologic profile and clinical implications","volume":"78","author":"Kangas","year":"2013","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0470","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.GME.0000063566.84134.98","article-title":"Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women","volume":"10","author":"Ylikorkala","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0475","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015229630260","article-title":"Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER\/PgR-positive advanced breast cancer","volume":"73","author":"Buzdar","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0480","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003495-200666020-00005","article-title":"Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women","volume":"66","author":"Vogelvang","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0485","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/OGX.0b013e31816400d7","article-title":"Selective estrogen receptor modulators: an update on recent clinical findings","volume":"63","author":"Shelly","year":"2008","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0490","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1067\/mob.2002.123938","article-title":"Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study","volume":"187","author":"Goldstein","year":"2002","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0495","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/13543784.15.3.317","article-title":"Arzoxifene: the development and clinical outcome of an ideal SERM","volume":"15","author":"Munster","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0500","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/gme.0b013e318223bbf4","article-title":"Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass","volume":"19","author":"Goldstein","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0505","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/13697137.2012.717994","article-title":"Effects of bazedoxifene\/conjugated estrogens on endometrial safety and bone in postmenopausal women","volume":"16","author":"Mirkin","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0510","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/gme.0b013e3181a7df0d","article-title":"Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene\/conjugated estrogens: a randomized, controlled trial","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0515","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0520","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2009.05.094","article-title":"Endometrial effects of a tissue selective estrogen complex (TSEC) containing bazedoxifene\/conjugated estrogens as a menopausal therapy","volume":"92","author":"Pickar","year":"2009","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0525","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene\/conjugated estrogens (BZA\/CE) for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0530","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/GME.0b013e318271f5e7","article-title":"Breast density changes in a randomized controlled trial evaluating bazedoxifene\/conjugated estrogens","volume":"20","author":"Harvey","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0535","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/AOG.0b013e31828c5974","article-title":"Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial","volume":"121","author":"Pinkerton","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0540","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.fertnstert.2009.05.093","article-title":"Bazedoxifene\/conjugated estrogens (BZA\/CE): incidence of uterine bleeding in postmenopausal women","volume":"92","author":"Archer","year":"2009","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jsbmb.2013.12.011_bib0545","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3109\/13697137.2013.810437","article-title":"Tissue selective estrogen complex combinations with bazedoxifene\/conjugated estrogens as a model","volume":"16","author":"Pinkerton","year":"2013","journal-title":"Climacteric"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076013002847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076013002847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:44:04Z","timestamp":1760744644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076013002847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":109,"alternative-id":["S0960076013002847"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2013.12.011","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of SERMs for treatment in postmenopausal women","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2013.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}